7 active not recruiting, 7 recruiting, 6 completed, 4 terminated. 14 Phase 2, 5 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Recurrent Hypopharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Hypopharyngeal Squamous Cell Carcinoma trials Research Report on Recurrent Hypopharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-19 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 188 | 2021-04-27 | 2026-10-21 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Efineptakin alfa - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Hyunseok Kang, MD | 4 | 2021-03-12 | 2025-02-14 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Communication Intervention, Watch video, Module completion of the Prepare to Care kit - Caregiver, Malignant Head and Neck Neoplasm | Not applicable | Completed | Wake Forest University Health Sciences | 35 | 2017-05-15 | 2023-01-09 |
| Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Not applicable | Terminated | Case Comprehensive Cancer Center | 3 | 2015-03-03 | 2019-01-24 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Cetuximab, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2011-02-10 | 2020-03-13 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Capecitabine, Vorinostat - Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2010-12-01 | 2017-04-14 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cisplatin, Docetaxel - Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx | Phase 2 | Completed | M.D. Anderson Cancer Center | 123 | 2010-02-05 | 2024-07-16 |
Showing 20 of 24. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (24) · Laryngeal Neoplasms (10) · Mouth Neoplasms (10) · Carcinoma (9) · Hypopharyngeal Neoplasms (9) · Lymphoid Interstitial Pneumonia (8) · Oropharyngeal Neoplasms (7) · Tongue Neoplasms (6) · Nasopharyngeal Carcinoma (5) · Salivary Gland Neoplasms (5) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Rectal Neoplasms (1) · Recurrence (1)
Carcinoma, Squamous Cell (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Neoplasms by Site (24) · Neoplasms, Glandular and Epithelial (24) · Head and Neck Neoplasms (23) · Mouth Diseases (16) · Stomatognathic Diseases (16) · Carcinoma (15) · Laryngeal Diseases (10) · Otorhinolaryngologic Diseases (10) · Otorhinolaryngologic Neoplasms (10) · Pharyngeal Diseases (10) · Pharyngeal Neoplasms (10) · Respiratory Tract Diseases (10)
Magnetic Resonance Spectroscopy (8) · Specimen Handling (8) · pembrolizumab (7) · Carboplatin (6) · 1,2-diaminocyclohexaneplatinum II citrate (5) · Cisplatin (5) · Platinum (5) · Cetuximab (4) · Docetaxel (3) · Radiosurgery (3) · (225)Ac-DOTA-c(RGDyK) (2) · Bevacizumab (2) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2)
National Cancer Institute (NCI) (14) · Emory University (4) · M.D. Anderson Cancer Center (2) · Case Comprehensive Cancer Center (1) · Hyunseok Kang, MD (1) · Marcelo Bonomi (1) · Wake Forest University Health Sciences (1)
United States (23) · Canada (2) · China (1) · Puerto Rico (1) · South Africa (1)
Yvonne M Mowery (2) · Aarti Bhatia (1) · Chandylen Nightingale (1) · Dan P Zandberg (1) · Dong M. Shin, MD, FACP, FAAAS (1) · Eric Chen (1) · Eric Winquist (1) · Erin M Bertino (1) · George Blumenschein, MD (1) · Greg Wolf (1) · Hyunseok Kang, MD (1) · Jacob S Thomas (1) · James Rocco (1) · Marcelo R Bonomi, MD (1)
PMID 31618129, PMID 35575280, PMID 37012550
P30CA138292 (4), U10CA180820 (3), N01CM00032 (2), UM1CA186690 (2), K24DC022077 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA012197 (1), P30CA014599 (1), P30CA016058 (1), P30CA043703 (1), P30CA046592 (1)